119 filings
6-K
CVAC
CureVac N.V.
28 May 24
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
4:56pm
6-K
CVAC
CureVac N.V.
24 May 24
Current report (foreign)
7:54am
6-K
CVAC
CureVac N.V.
23 May 24
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
4:27pm
6-K
CVAC
CureVac N.V.
23 May 24
Current report (foreign)
4:09pm
6-K
CVAC
CureVac N.V.
24 Apr 24
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
4:30pm
6-K
pvvmzjxti2ywn8
24 Apr 24
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
4:20pm
6-K
r74xngy1
24 Apr 24
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
4:15pm
6-K
hy7d7n aboxg4
16 Apr 24
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4:15pm
6-K
rnh6s2
4 Apr 24
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
4:15pm
6-K
sap ka5adybflgus
17 Jan 24
CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock
9:02am
6-K
eob9tzr
5 Jan 24
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development
4:15pm
6-K
vups80muytxr
19 Dec 23
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
4:30pm
6-K
kk1b0 117uliz3
14 Nov 23
Current report (foreign)
4:15pm
6-K
i0iyahuq7dna0 dab
14 Nov 23
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
4:15pm
6-K
xhuccu6w0nmpqmvzt
1 Nov 23
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
4:45pm
6-K
0dpwnf7cb3xn9fpp ug
28 Sep 23
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
4:30pm
6-K
i41sik nfi66niy
12 Sep 23
Current report (foreign)
4:30pm
6-K
s5ahkv3goj12pavj
17 Aug 23
Current report (foreign)
4:30pm
6-K
hmg 77hdml
17 Aug 23
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
4:30pm
6-K
p5q 0ubvenrpjf
1 Aug 23
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
4:15pm